Atossa Genetics Announces Warrant Exercises
30 juin 2017 10h36 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jun 30, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer...
Atossa Genetics Receives Positive Safety Committee Assessment of First Cohort Receiving Oral Formulation of Endoxifen in Phase 1 Dose Escalation Study
26 juin 2017 08h00 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jun 26, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer...
Atossa Genetics to Present at the LD Micro Invitational on June 6, 2017
01 juin 2017 08h00 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Jun 1, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
Atossa Genetics Completes Enrollment in Topical Arm of Endoxifen Phase 1 Study
19 mai 2017 08h00 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 19, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
Atossa Genetics Announces First Quarter 2017 Financial Results and Provides Company Update
11 mai 2017 17h30 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 11, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced First Quarter ended March 31, 2017 financial results and provided an update on recent company...
Atossa Genetics Receives Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
10 mai 2017 08h00 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 10, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company, today announced that it has received the second positive interim review on...
Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study
09 mai 2017 08h00 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - May 9, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and...
Atossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study
20 avr. 2017 08h15 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Apr 20, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company, today announced that it has received a positive interim review on its...
Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study
04 avr. 2017 08h15 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Apr 4, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it has fully enrolled the first of six cohorts (eight participants per cohort) in its Phase 1...
Atossa Genetics Closes Public Offering
03 avr. 2017 16h05 HE
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwired - Apr 3, 2017) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced the closing of its previously announced underwritten public offering with gross proceeds to Atossa of...